Johnson Johnson AbbVie: Paths to Pharma Dominance
Johnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
An approachable overview comparing passive retirement investing using index funds versus ETFs, highlighting costs, flexibility, and long-term potential.
25,613 articlesJohnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
Fundstrat co-founder Tom Lee points to the ETH/BTC ratio as a sign of a potential leadership shift in crypto, suggest...
U.S. stocks climbed on Tuesday as inflation cooled more than expected, helping the S&P 500 regain ground. Futures poi...
SpaceX is attracting renewed investor interest as revenue streams expand beyond launches. With Starlink, NASA deals, ...
The World Cup has unleashed a vigorous rise in prediction markets, with activity hitting a sizable share of US sports...
Microsoft leans on three strategic ties—OpenAI, hardware collaboration with AMD, and Copilot enterprise adoption—to s...
Senate Democrats allege the White House granted tariff exemptions to firms tied to donors, sparking a bipartisan push...
A reserves-and-resources update put Coeur Mining back in focus, with millions of ounces of gold on the books and a pr...
President Trump announces a new tariff package under a different statute, prompting questions about legality and mark...
Lenders and regulators are debating a shift to single credit bureau pulls: for government-backed loans, a change that...
Amazon unveils a sweeping $200 billion capex plan focused on AWS and AI infra, prompting investor debate on the compa...
Nvidia’s CEO just handed investors a fresh signal about AI demand and Nvidia’s path forward. This guide breaks down t...